Overview

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

Status:
Completed

Trial end date:
2021-06-22

Target enrollment:

Participant gender:

Summary

The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with moderately to severely active rheumatoid arthritis.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Adalimumab
Methotrexate